NV-QUECTEL-WIRELESS
4.1.2023 14:01:53 CET | Business Wire | Press release
CES, Quectel Wireless Solutions, a global IoT and automotive solutions provider, today announces its new automotive grade 5G NR modules, the AG59x series. The new modules deliver a wide range of enhancements including multi-gigabit cellular connectivity, C-V2X PC5 direct communications, improved location services, a high-performance multicore application processor as well as strengthened security, making it an ideal solution in supporting the next generation automotive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005509/en/
(Graphic: Business Wire)
Based on the AEC-Q100 qualified Qualcomm chipsets, the new range of modules include the AG59xH series, which integrates the Qualcomm SA525M and the AG59xE series featuring the Qualcomm SA522M inside. Similar to Quectel’s other automotive products, the AG59x modules comply with the international IATF 16949:2016 automotive quality management system to address the demanding requirements of automotive devices. Featuring high robustness, the AG59x series delivers strong performance even under high temperature environments.
“We are very excited to bring the highly anticipated 5G NR Release 16 module to global automotive markets. Its significant improvements in latency and ultra-reliability are critical in supporting autonomous driving,” said Manfred Lindacher, Vice President of Global Sales, Automotive International, Quectel Wireless Solutions. “Combined with its many other advantages, our AG59x series will be an excellent choice for a wide range of automotive applications including telematics boxes, telematics control units, C-V2X systems, on-board units, and roadside units.”
Meeting the 3GPP Release 16 specification and supporting both 5G NR standalone (SA) and non-standalone (NSA) modes, the AG59x modules are backward-compatible with existing LTE, WCDMA and GSM networks, allowing them to be connected in areas without current 5G NR deployment. Additionally, its Dual SIM Dual Standby (DSDS) technology can help tackle poor signal coverage when needed.
The AG59x supports 4 x 4 downlink multiple input multiple output (MIMO) technology which greatly improves wireless communication performance and optimizes data speeds. The AG59xH delivers maximum downlink rates of 4.3Gbps and uplink rates of 1Gbps for 5G NR, while the AG59xE provides up to 2.4Gbps peak downlink rate and 550Mbps uplink rate. Their faster data speeds ensure that user emergency data and diagnostic data can be transferred in real time for increased reliability.
Supporting optional C-V2X PC5 direct communications, the AG59x brings superior performance in vehicle-to-vehicle (V2V) and vehicle-to-roadside infrastructure (V2I) communications for improved traffic efficiency and safety. The module integrates a powerful application processor with up to 20KDMIPS computing power available to run C-V2X stack and applications. It also has an integrated ECDSA engine fulfill C-V2X verification capability.
Additionally, the highly integrated AG59x module provides flexible GNSS positioning services including L1+L5 / L1+L2 (optional) dual frequency GNSS, dead reckoning (DR), and PPE + Data Correction Service to achieve quick and precise location positioning services.
Available in LGA packages, the AG59x is pin-to-pin compatible with Quectel’s previous generation 5G NR automotive modules AG55xQ and AG57xQ, which allows global OEM and Tier 1 customers to upgrade their devices easily and seamlessly through a simple drop-in replacement. The AG59x provides a variety of interfaces including PCIe 3.0, USB 2.0 & 3.1, SDIO, I2S, SPI, I2C, UART, PCM, ADC, (U)SIM, 1PPS, GPIOs. It also supports RGMII and SGMII interfaces at the same time which greatly improves the adaptability of in-vehicle Ethernet.
The Quectel AG59x series is complemented by its range of high-performance antennas, already in use in the autonomous car market. Customized antennas are also supplied to fit for various vehicle setup environments. In particular, Quectel’s range of combo antennas, which integrate multiple technologies such as 5G, 4G, and GNSS, offer a highly flexible and reliable antenna solution for automotive applications.
Engineering samples of the AG59x modules will be available in the first half of 2023, with multiple variants targeting global markets.
Find out more about this module series at CES 2023 on booth 10862.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services.
Our growing global team of over 6,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005509/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom